PPB Kenya Clinical Trial Authorization

Every interventional clinical trial conducted in Kenya has to clear two separate approvals before it can start: a product- and protocol-level clinical trial authorization from the Pharmacy and Poisons Board (PPB), Kenya’s national medicines regulatory authority, and an independent ethics clearance issued through Kenya’s separate research-ethics and research-permitting system. This guide walks through what the PPB is, its legal basis, how the two-track authorization structure fits together, and where sponsors should go to confirm current procedural detail rather than treat any single summary as final.

What the Pharmacy and Poisons Board Is

The Pharmacy and Poisons Board is Kenya’s national medicines regulatory authority, established under the Pharmacy and Poisons Act, Chapter 244 of the Laws of Kenya, and operating under Kenya’s Ministry of Health. The Act gives the PPB responsibility for regulating the practice of pharmacy and the manufacture, importation, distribution, and trade in drugs and poisons in Kenya, and defines a clinical trial in broad, GCP-consistent terms: a systematic study of a pharmaceutical product in human subjects intended to discover or verify its effects, identify adverse reactions, or study its absorption, distribution, metabolism, and excretion, in order to establish safety and efficacy. Because it controls the legal ability to import, manufacture, or distribute an investigational product in Kenya, the PPB is the gate a sponsor cannot bypass: no investigational drug, biologic, vaccine, or device can lawfully move into a Kenyan trial site without PPB clinical trial authorization.

The Two-Track Structure: PPB Authorization and Ethics/Research-Permit Clearance

Kenya’s oversight structure separates product-level regulatory review from human-subjects ethics review, the same basic architecture used across most jurisdictions with mature clinical trial systems (see the sibling guides on South Africa’s SAHPRA pathway and Nigeria’s NAFDAC pathway for how the equivalent split works elsewhere in Africa):

PPB clinical trial authorization reviews the protocol, investigator’s brochure, product quality and manufacturing information, and informed consent materials from a product-safety and scientific-quality standpoint, and is the approval that permits an investigational product to legally enter or be manufactured in Kenya for trial use.
Ethics and research-permit clearance runs through Kenya’s separate research-governance system built around the National Commission for Science, Technology and Innovation (NACOSTI). Applicants must first obtain approval from an Institutional Scientific and Ethics Review Committee (ISERC) accredited under the standards set by NACOSTI’s National Scientific and Ethics Committee (NSEC), and ethics clearance is generally expected before NACOSTI will consider issuing the separate research permit/license that authorizes the research itself to proceed in Kenya.

These two tracks are complementary, not substitutes for one another: PPB authorization does not remove the need for ISERC ethics clearance and a NACOSTI research permit, and ethics/research-permit clearance does not remove the need for PPB authorization of the investigational product. Sponsors planning a Kenyan site should budget for both tracks from the same start date rather than sequencing one strictly after the other.

Disambiguation note: NACOSTI’s research-permitting role described here is a distinct function from Kenya’s National Research Fund (NRF), which is a research-funding body, not a regulatory or ethics-permitting one. Don’t conflate the two when advising a Kenya-based site: NRF funds research; NACOSTI (via NSEC-accredited ISERCs and its own research-permit process) and the PPB are what actually authorize a clinical trial to run.

The PPB Clinical Trial Authorization Pathway

The PPB has published dedicated clinical trial guidance, including Guidelines for the Conduct of Clinical Trials in Kenya, and operates a dedicated online clinical trials register/application system (accessible via the PPB’s clinical trials portal) through which sponsors and investigators are expected to submit clinical trial applications and supporting documentation. At a minimum, sponsors preparing a submission should expect the PPB to require the trial protocol, investigator’s brochure, product quality/manufacturing (CMC) documentation, informed consent materials, and evidence that the ethics-review workstream has been initiated, consistent with the dual-track structure above.

This guide deliberately does not state specific submission fees, review-timeline commitments, or a fixed list of required forms as fixed facts: PPB guidelines, fee schedules, and the online submission portal’s exact requirements are revised periodically, and a sponsor should confirm current requirements directly against the PPB’s own published guidance and portal before finalizing a submission timeline, rather than relying on a third-party summary that may lag a revision.

Good Clinical Practice Expectations

As with most national regulators overseeing clinical trials, Kenya’s framework expects trial conduct to follow Good Clinical Practice (GCP) standards and proper informed consent procedures throughout. Sponsors already building trial quality-management systems around the International Council for Harmonisation’s GCP guideline — whether the earlier ICH E6(R2) addendum or the newer ICH E6(R3) revision — should confirm the PPB’s own current guidance for any Kenya-specific procedural detail, rather than assuming international GCP alignment substitutes for a locally required document or step.

Practical Checklist for Sponsors Planning a Kenyan Site

Confirm the PPB’s current clinical trial application requirements, submission channel, and any published fee schedule directly from the PPB’s own guidance before finalizing a project timeline — do not rely on a static summary for figures that change with guideline revisions.
Initiate ISERC ethics review, and the associated NACOSTI research-permit process, in parallel with — not strictly after — the PPB regulatory submission, since PPB review typically expects evidence the ethics track is already underway.
Do not import, procure, or locally manufacture investigational product for a Kenyan trial site until PPB clinical trial authorization has actually been issued.
Keep NACOSTI’s research-permit/ethics-accreditation role and the National Research Fund’s (NRF) funding role clearly separated in any internal regulatory-strategy documentation — they are different bodies with different functions, despite both appearing frequently in Kenya-focused research administration.
For multi-country African trials, track regional harmonization developments (including the African Medicines Agency and East African regulatory cooperation) that may affect how a Kenyan approval interacts with approvals in neighboring markets.

Frequently Asked Questions

Is the Pharmacy and Poisons Board the only approval a clinical trial needs in Kenya?

No. PPB clinical trial authorization covers the investigational product and protocol from a regulatory and scientific standpoint. A Kenyan trial also needs ethics clearance from an accredited Institutional Scientific and Ethics Review Committee (ISERC) and, generally, a research permit issued through Kenya’s National Commission for Science, Technology and Innovation (NACOSTI). Both tracks are required; neither substitutes for the other.

What law establishes the Pharmacy and Poisons Board’s authority?

The PPB operates under the Pharmacy and Poisons Act, Chapter 244 of the Laws of Kenya, which gives it authority over the practice of pharmacy and the manufacture, importation, distribution, and trade in drugs and poisons, including investigational products used in clinical trials.

Is Kenya’s National Research Fund (NRF) involved in clinical trial approval?

No. The NRF is a national research-funding body; it does not authorize or approve clinical trials. Clinical trial authorization runs through the PPB, and ethics/research-permit clearance runs through NACOSTI-accredited ISERCs and NACOSTI’s own research-permit process. See CASRAI’s separate guide to NRF Kenya funding for that distinct topic.

Where should sponsors go for the current, authoritative PPB submission requirements?

Directly to the Pharmacy and Poisons Board’s own published guidelines and its clinical trials online submission portal. Because fee schedules, forms, and procedural detail are revised periodically, a third-party summary (including this guide) should not be treated as a substitute for checking the PPB’s current published guidance before filing.

Related Country Regulatory Pathway Guides

This guide is part of CASRAI’s series on national clinical trial regulatory pathways. See also: